Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review Article
  • Published:

The role of C-reactive protein as an inflammatory marker in gastrointestinal diseases

Nature Clinical Practice Gastroenterology & Hepatology volume 2, pages 580–586 (2005)Cite this article

Abstract

C-reactive protein (CRP) is an acute-phase protein that is produced in large amounts by hepatocytes, upon stimulation by the cytokines interleukin-6, tumor-necrosis-factor-α and interleukin-1β, during an acute-phase response. CRP is an objective marker of inflammation and, in gastrointestinal diseases such as Crohn's disease and acute pancreatitis, its levels correlate well with clinical disease activity. In contrast to its use as a marker in Crohn's disease, however, CRP is a less reliable marker of inflammation and disease activity in patients with ulcerative colitis, except perhaps for severe, extensive colitis. The increased production of CRP after an acute-phase stimulus, such as active gut inflammation, might explain why strong anti-inflammatory agents, such as anti-tumor-necrosis-factor-α antibodies and other biologic agents, work particularly well in patients with increased levels of CRP. CRP is also useful as a laboratory marker to predict prognosis and relapse in patients with Crohn's disease and acute pancreatitis. Elevated CRP levels have been associated with an increased risk of colorectal cancer and are a marker of poor prognosis, indicating more advanced disease and, possibly, reduced survival. An important question that remains is how often CRP levels should be measured. Until there are more data, the use of CRP and of other biomarkers should be seen as an additional tool that aids clinical observation and physical examination, but that cannot replace it.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Tall AR (2004) C-reactive protein reassessed. N Engl J Med 350: 1450–1452

    Article  CAS  Google Scholar 

  2. Pepys MB et al. (1977) Immunological studies in inflammatory bowel disease. In: Immunology of the Gut, Ciba Foundation Symposium 283–297 (Eds Porter R and Knight J). Amsterdam: Elsevier/Excerpta Medica

    Google Scholar 

  3. Vigushin DM et al. (1993) Metabolic and scintigraphic studies of radioiodinated human C-reactive protein in health and disease. J Clin Invest 91: 1351–1357

    Article  CAS  Google Scholar 

  4. Saverymuttu SH et al. (1986) Differing acute phase responses in Crohn's disease and ulcerative colitis. Gut 27: 809–813

    Article  CAS  Google Scholar 

  5. Rogler G (2004) Update in inflammatory bowel disease pathogenesis. Curr Opin Gastroenterol 20: 311–317

    Article  Google Scholar 

  6. Gross V et al. (1992) Evidence for continuous stimulation of interleukin-6 production in Crohn's disease. Gastroenterology 102: 514–519

    Article  CAS  Google Scholar 

  7. Shine B et al. (1985) C-reactive protein as an aid in the differentiation of functional and inflammatory bowel disorders. Clin Chim Acta 148: 105–109

    Article  CAS  Google Scholar 

  8. Beattie RM et al. (1995) Indications for investigation of chronic gastrointestinal symptoms. Arch Dis Child 73: 354–355

    Article  CAS  Google Scholar 

  9. Poullis AP et al. (2002) A new, highly sensitive assay for C-reactive protein can aid the differentiation of inflammatory bowel disorders from constipation- and diarrhoea-predominant functional bowel disorders. Eur J Gastroenterol Hepatol 14: 409–412

    Article  CAS  Google Scholar 

  10. Fagan EA et al. (1982) Serum levels of C-reactive protein in Crohn's disease and ulcerative colitis. Eur J Clin Invest 12: 351–359

    Article  CAS  Google Scholar 

  11. Andre C et al. (1981) Assessment of appropriate laboratory measurements to supplement the Crohn's disease acitivity index. Gut 22: 571–574

    Article  CAS  Google Scholar 

  12. Tromm A et al. (1992) Evaluation of different laboratory tests and activity indices reflecting the inflammatory activity of Crohn's disease. Scand J Gastroenterol 27: 774–778

    Article  CAS  Google Scholar 

  13. Ricci G et al. (1995) Comparison of serum total sialic acid, C-reactive protein, alpha 1-acid glycoprotein and beta 2-microglobulin in patients with non-malignant bowel diseases. Biomed Pharmacother 49: 259–262

    Article  CAS  Google Scholar 

  14. Solem CA et al. (2005) Correlation of C-reactive protein (CRP) with clinical, radiographic, and endoscopic activity in inflammatory bowel disease (IBD). Inflamm Bowel Dis 11: 707–712

    Article  Google Scholar 

  15. Ridker PM and Morrow DA (2003) C-reactive protein, inflammation, and coronary risk. Cardiol Clin 21: 315–325

    Article  Google Scholar 

  16. Danesh J et al. (2004) C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 350: 1387–1397

    Article  CAS  Google Scholar 

  17. Bataille R et al. (1992) C-reactive protein and beta-2 microglobulin produce a simple and powerful myeloma staging system. Blood 80: 733–737

    CAS  PubMed  Google Scholar 

  18. Boirivant M et al. (1988) The clinical significance of serum C reactive protein levels in Crohn's disease. Results of a prospective longitudinal study. J Clin Gastroenterol 10: 401–405

    Article  CAS  Google Scholar 

  19. Consigny Y et al. (2001) Biological markers of short term relapse in Crohn's disease (CD) [Abstract]. Gastroenterology 20 (Suppl): A53

    Google Scholar 

  20. Brignola C et al. (1986) A laboratory index for predicting relapse in asymptomatic patients with Crohn's disease. Gastroenterology 91: 1490–1494

    Article  CAS  Google Scholar 

  21. Travis SP et al. (1996) Predicting outcome in severe ulcerative colitis. Gut 38: 905–910

    Article  CAS  Google Scholar 

  22. Targan SR et al. (1997) A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 337: 1029–1035

    Article  CAS  Google Scholar 

  23. Present DH et al. (1999) Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 340: 1398–1405

    Article  CAS  Google Scholar 

  24. Hanauer SB et al. (2002) Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 359: 1541–1549

    Article  CAS  Google Scholar 

  25. Sands BE et al. (2004) Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 350: 876–885

    Article  CAS  Google Scholar 

  26. Louis E et al. (2002) A positive response to infliximab in Crohn disease: association with a higher systemic inflammation before treatment but not with -308 TNF gene polymorphism. Scand J Gastroenterol 37: 818–824

    Article  CAS  Google Scholar 

  27. Sandborn WJ et al. (2004) CDP571, a humanised monoclonal antibody to tumour necrosis factor alpha, for moderate to severe Crohn's disease: a randomised, double blind, placebo controlled trial. Gut 53: 1485–1493

    Article  CAS  Google Scholar 

  28. Schreiber S et al. (2003) Safety of CDP870, a pegylated humanized anti-TNF antibody fragment in Crohn's disease [Abstract]. Gut 52 (Suppl): A215

    Google Scholar 

  29. Rutgeerts P et al. (2003) Subanalysis from a phase 3 study on the evaluation of natalizumab in active Crohn's disease [Abstract]. Gut 52 (Suppl): A239

    Google Scholar 

  30. Dervenis C et al. (1999) Diagnosis, objective assessment of severity, and management of acute pancreatitis. Santorini consensus conference. Int J Pancreatol 25: 195–210

    CAS  PubMed  Google Scholar 

  31. Wilson C et al. (1989) C-reactive protein, antiproteases and complement factors as objective markers of severity in acute pancreatitis. Br J Surg 76: 177–181

    Article  CAS  Google Scholar 

  32. Viedma JA et al. (1992) Role of interleukin-6 in acute pancreatitis. Comparison with C-reactive protein and phospholipase A. Gut 33: 1264–1267

    Article  CAS  Google Scholar 

  33. Buchler M et al. (1986) Sensitivity of antiproteases, complement factors and C-reactive protein in detecting pancreatic necrosis. Results of a prospective clinical study. Int J Pancreatol 1: 227–235

    CAS  PubMed  Google Scholar 

  34. Werner J et al. (2003) Useful markers for predicting severity and monitoring progression of acute pancreatitis. Pancreatology 3: 115–127

    Article  CAS  Google Scholar 

  35. Puolakkainen P et al. (1987) C -reactive protein (CRP) and serum phospholipase A2 in the assessment of the severity of acute pancreatitis. Gut 28: 764–771

    Article  CAS  Google Scholar 

  36. Windsor JA (2000) Search for prognostic markers for acute pancreatitis. Lancet 355: 1924–1925

    Article  CAS  Google Scholar 

  37. Paajanen H et al. (1995) Serum tumour necrosis factor compared with C-reactive protein in the early assessment of severity of acute pancreatitis. Br J Surg 82: 271–273

    Article  CAS  Google Scholar 

  38. Gross V et al. (1990) Granulocyte elastase in assessment of severity of acute pancreatitis. Comparison with acute-phase proteins C-reactive protein, alpha 1-antitrypsin, and protease inhibitor alpha 2-macroglobulin. Dig Dis Sci 35: 97–105

    Article  CAS  Google Scholar 

  39. Hamalainen MT et al. (2002) Do normal leukocyte count and C-reactive protein on admission to hospital exclude a life-threatening attack of acute pancreatitis? Scand J Surg 91: 353–356

    Article  CAS  Google Scholar 

  40. Imamura T et al. (2002) Significance of measurement of high-sensitivity C-reactive protein in acute pancreatitis. J Gastroenterol 37: 935–938

    Article  CAS  Google Scholar 

  41. Kiviniemi H et al. (1994) Acute phase response in patients with uncomplicated and complicated endoscopic retrogradic cholangiopancreaticography. HPB Surg 8: 129–131

    Article  CAS  Google Scholar 

  42. Oezcueruemez-Porsch M et al. (1998) Diagnostic relevance of interleukin pattern, acute-phase proteins, and procalcitonin in early phase of post-ERCP pancreatitis. Dig Dis Sci 43: 1763–1769

    Article  CAS  Google Scholar 

  43. Kaw M and Singh S (2001) Serum lipase, C-reactive protein, and interleukin-6 levels in ERCP-induced pancreatitis. Gastrointest Endosc 54: 435–440

    Article  CAS  Google Scholar 

  44. Baron JA et al. (2003) A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 348: 891–899

    Article  CAS  Google Scholar 

  45. Giardiello FM et al. (1993) Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 328: 1313–1316

    Article  CAS  Google Scholar 

  46. Steinbach G et al. (2000) The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 342: 1946–1952

    Article  CAS  Google Scholar 

  47. Erlinger TP et al. (2004) C-reactive protein and the risk of incident colorectal cancer. JAMA 291: 585–590

    Article  CAS  Google Scholar 

  48. Zhang SM et al. (2005) C-reactive protein levels are not associated with increased risk for colorectal cancer in women. Ann Intern Med 142: 425–432

    Article  CAS  Google Scholar 

  49. Nozoe T et al. (1998) Significance of preoperative elevation of serum C-reactive protein as an indicator for prognosis in colorectal cancer. Am J Surg 176: 335–338

    Article  CAS  Google Scholar 

  50. Chung YC and Chang YF (2003) Serum C-reactive protein correlates with survival in colorectal cancer patients but is not an independent prognostic indicator. Eur J Gastroenterol Hepatol 15: 369–373

    Article  CAS  Google Scholar 

  51. McMillan DC et al. (2003) Systemic inflammatory response predicts survival following curative resection of colorectal cancer. Br J Surg 90: 215–219

    Article  CAS  Google Scholar 

  52. Nikiteas NI et al. (2005) Serum IL-6, TNF alpha and CRP levels in Greek colorectal cancer patients: prognostic implications. World J Gastroenterol 11: 1639–1643

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Assistant Professor of Medicine Department of Medicine, Division of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium

    Séverine Vermeire

  2. Associate Professor Department of Medicine, Division of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium

    Gert Van Assche

  3. full Professor in the Department of Medicine, Division of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium

    Paul Rutgeerts

Authors
  1. Séverine Vermeire
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gert Van Assche
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Paul Rutgeerts
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Séverine Vermeire.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Vermeire, S., Van Assche, G. & Rutgeerts, P. The role of C-reactive protein as an inflammatory marker in gastrointestinal diseases. Nat Rev Gastroenterol Hepatol 2, 580–586 (2005). https://doi.org/10.1038/ncpgasthep0359

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpgasthep0359

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing